

## Synthesis of steroidal saponins bearing an aromatic E ring

Ziyu Wang, Ming Li, Xueting Liu and Biao Yu\*

State Key Laboratory of Bio-organic and Natural Products Chemistry, Shanghai Institute of Organic Chemistry, Chinese Academy of Sciences, Shanghai 200032, China

Received 18 July 2007; revised 7 August 2007; accepted 8 August 2007

Available online 10 August 2007


**Abstract**—A facile synthetic approach toward the steroidal saponins bearing an aromatic E ring was developed starting from the readily available spirostan saponin.

© 2007 Elsevier Ltd. All rights reserved.

Steroidal saponins constitute an extremely diverse and abundant family of plant metabolites, with a broad range of biological activities.<sup>1</sup> The steroidal aglycones are biosynthetically derived from the 30-carbon oxidosqualene; removal of the three methyl groups of a lanostane precursor produces the 27-carbon steroidal skeleton.<sup>2</sup> Subsequent degradation may take place to form steroids with less than 27-carbons. In 2003, Nohara et al. disclosed from *Solanum aethiopicum* three steroidal saponins having novel 29/30-carbon skeletons.<sup>3</sup> These saponin compounds, named aethioside A–C, bearing an additional aromatized E ring are unprecedented. In 2005, an additional congener was

identified from *Paris polyphylla*.<sup>4</sup> The origin of the additional carbons and the bio-formation of the aromatized E ring are yet to be known. Herein we report a facile approach toward the synthesis of the steroidal saponins bearing an aromatic E ring.


Recently, we have developed an effective approach for the conversion of the ready available spirostan saponins (e.g., **4**; Fig. 1) into their furostan counterparts,<sup>5</sup> where an oxidative ring open of the spirostan E and F rings was employed to provide a 16,22-di-one (e.g., **3**) as a versatile intermediate for further elaboration.<sup>5,6</sup> We envisioned the ready formation of the furan or



**Figure 1.** The natural steroidal saponin aethioside C (**1**) and its retrosynthetic analysis.

**Keywords:** Steroidal saponin; Diels–Alder reaction; Thiophene; Furan; Aethioside.

\* Corresponding author. Tel.: +21 64163300x1407; fax: +21 64166128; e-mail: [byu@mail.sioc.ac.cn](mailto:byu@mail.sioc.ac.cn)




**Scheme 1.** Reagents and conditions: (a) *p*-TsOH (cat.), Ac<sub>2</sub>O, reflux, 2 h, 65%; (b) Lawesson's reagent, 4 Å MS, toluene, reflux, overnight, 78%.

thiophene derivatives (e.g., **2**) from the 16,22-di-one to obtain the novel steroidal saponin derivatives with a heterocyclic E ring. Moreover, an oxidative Diels–Alder cycloaddition of the furan/thiophene E ring with an acetylene dienophile would generate a benzene E ring, thus providing an access to the unusual aethioside-type saponins.

We first tried the furan/thiophene ring formation on the 16,22-di-one-3,26-bisglycoside **3a**, a precursor to the furostan saponins (**Scheme 1**).<sup>5</sup> Thus, reflux of 16,22-di-one **3a** in Ac<sub>2</sub>O in the presence of a catalytic amount of *p*-toluenesulfonic acid for two hours afforded the desired furan derivative **2a** as a major product in 65% isolated yield.<sup>7</sup> However, this furan derivative decom-

posed quickly at storage or under conditions for the subsequent Diels–Alder reaction. Alternatively, dione **3a** was treated with Lawesson's reagent in the presence of 4 Å MS in toluene,<sup>8</sup> the desired thiophene derivative **2b** was obtained in a good 78% yield. Nevertheless, under the oxidative Diels–Alder cycloaddition conditions (*m*-CPBA, BF<sub>3</sub>·Et<sub>2</sub>O, dimethyl acetylenedicarboxylate, or methyl propiolate), which have been well documented by Mataka et al.,<sup>9</sup> the thiophene derivative **2b** proceeded into a complex mixture.

The bulky 2,3,4,6-tetra-*O*-benzoyl-β-D-glucopyranosyl residue at the 26-OH that is proximal to the thiophene ring in **2b** might play a detrimental role in the above reaction. Thus, we attempted the transformation from



**Scheme 2.** Reagents and conditions: (a) Lawesson's reagent, 4 Å MS, toluene, reflux, overnight, 90%; (b) dimethyl acetylenedicarboxylate or methyl propiolate, BF<sub>3</sub>·Et<sub>2</sub>O, *m*-CPBA, 4 Å MS, toluene, –70 to 0 °C, 72% (for **7**, overnight); 56% (for **8a/b**, a week); (c) NaOMe, MeOH/CH<sub>2</sub>Cl<sub>2</sub> (v:v 4:1), rt, overnight, 72% (for **9**); 92% (for **10a/b**); (d) TMSOTf (0.3 equiv), 4 Å MS, CH<sub>2</sub>Cl<sub>2</sub>, –40 °C to rt, overnight, 82% (for **12**); 79% (for **13a/b**).

16,22-di-one-26-*O*-acetate **5**, which was readily prepared from the spirostan dioscin pivalate **4** in three steps and 68% yield (Scheme 2).<sup>5</sup> Treatment of 16,22-di-one **5** with Lawesson's reagent provided the thiophene derivative **6** in an excellent 90% yield. Thiophene **6** was then applied to the Mataka's cycloaddition conditions, where the thiophene ring was expected to be selectively oxidized at low temperature with *m*-CPBA in the presence of BF<sub>3</sub>·Et<sub>2</sub>O to yield the thiophene *S*-monoxide; subsequent addition to a dienophile and extrusion of the resulting O=S-bridge in the [4+2]-cycloadduct under the oxidative surroundings should provide the desired benzene derivative.<sup>9</sup> Indeed, when dimethyl acetylenedicarboxylate was used as a dienophile and toluene as the solvent (overnight), the corresponding benzene derivative **7** was isolated in a good 72% yield. However, under similar conditions, the reaction with methyl propiolate was found much sluggish, providing a pair of the inseparable regio-isomers (**8a/b**, 3:7) in 56% yield over a week of reaction. Selective removal of the 26-*O*-acetyl group in **7** and **8a/b** was achieved with NaOMe in MeOH/CH<sub>2</sub>Cl<sub>2</sub>, providing **9** and **10a/b**. Glycosylation of the 26-ols (**9** and **10a/b**) with 2,3,4,6-tetra-*O*-benzoyl-*D*-glucopyranosyl trichloroacetimidate **11** under the promotion of TMSOTf afforded the desired bisglycosides **12** and **13a/b** in about 80% yield.<sup>10</sup> Final removal of the ester groups on **12** and **13a/b**, and the previous compounds **2b**, **6**, **7**, and **8a/b** as well, with LiOH in a mixture solvent of MeOH/THF/H<sub>2</sub>O (to compromise the solubility), afforded novel steroidal saponins with a benzene or thiophene E ring.

In summary, we have shown the ready conversion of a spirostan saponin into the novel saponin derivatives with an aromatized E ring, including the furan, thiophene, and benzene ring. To achieve the effective synthesis of the unusual aethioside-type saponins, the regioselectivity in the Diels–Alder cycloaddition with the E-thiophene-ring requires improvement. In addition, diversity-oriented synthesis based on the present chemistry and the screening of the bioactivities of these compounds are our undergoing projects.

### Acknowledgments

Financial support from the Chinese Academy of Sciences (KGCX2-SW-213 and KSCX2-YW-R-23) and the National Natural Science Foundation of China (20321202) are gratefully acknowledged. X.L. also thanks the China Postdoctoral Science Foundation for a grant.

### References and notes

- Hostettmann, K.; Marston, A. *Saponins*; Cambridge University Press: Cambridge, UK, 1995.
- Vincken, J.-P.; Heng, L.; Groot, A. D.; Gruppen, H. *Phytochemistry* **2007**, *68*, 275–297.
- Tagawa, C.; Okawa, M.; Ikeda, T.; Yoshida, T.; Nohara, T. *Tetrahedron Lett.* **2003**, *44*, 4839–4841.
- Huang, Y.; Wang, Q.; Ye, W.-C.; Cui, L. *J. Chin. J. Nat. Med.* **2005**, *3*, 138–140.
- Li, M.; Yu, B. *Org. Lett.* **2006**, *8*, 2679–2682.
- (a) Bovicelli, P.; Lupattelli, P.; Fracassi, D.; Mincione, E. *Tetrahedron Lett.* **1994**, *35*, 935–938; (b) Yu, B.; Liao, J.; Zhang, J.; Hui, Y. *Tetrahedron Lett.* **2001**, *42*, 77–79; (c) Cheng, M. S.; Wang, Q. L.; Tian, Q.; Song, H. Y.; Liu, Y. X.; Li, Q.; Xu, X.; Miao, H. D.; Yao, X. S.; Yang, Z. *J. Org. Chem.* **2003**, *68*, 3658–3662.
- Chaosuancharoen, N.; Kongkathip, N.; Kongkathip, B. *Synth. Commun.* **2004**, *34*, 961–983.
- Jesberger, M.; Davis, T. P.; Barner, L. *Synthesis* **2003**, 1929–1958.
- (a) Li, Y.-Q.; Thiemann, T.; Mimura, K.; Sawada, T.; Mataka, S.; Tashiro, M. *Eur. J. Org. Chem.* **1998**, 1841–1850; (b) Thiemann, T.; Li, Y.-Q.; Thiemann, C.; Sawada, T.; Ohira, D.; Tashiro, M.; Mataka, S. *Heterocycles* **2000**, *52*, 1215–1230.
- Selected data for the new compounds. Compound **2a**: [ $\alpha$ ]<sub>D</sub><sup>25</sup> –19 (*c* 0.7, CHCl<sub>3</sub>); <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>):  $\delta$  8.00–7.72 (m, 8H), 7.52–7.17 (m, 12H), 5.83 (t, 1H, *J* = 9.6 Hz), 5.61 (t, 1H, *J* = 9.9 Hz), 5.47 (t, 1H, *J* = 8.4 Hz), 5.37–5.20 (m, 3H), 5.19–5.11 (m, 2H), 5.09–4.97 (m, 2H), 4.93 (s, 1H), 4.81 (d, 1H, *J* = 1.5 Hz), 4.76 (d, 1H, *J* = 8.1 Hz), 4.70 (s, 1H), 4.61–4.50 (m, 2H), 4.49–4.30 (m, 3H), 4.25–4.15 (m, 1H), 4.14–4.03 (m, 1H), 3.92–3.80 (m, 1H), 3.76–3.63 (m, 3H), 3.63–3.46 (m, 2H), 3.40–3.30 (m, 1H), 2.45–2.28 (m, 5H), 2.28–2.10 (m, 2H), 2.00–1.80 (m, 5H), 1.73 (s, 3H), 0.97 (s, 3H), 0.82 (s, 3H), 0.74 (d, 3H, *J* = 6.3 Hz); <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>):  $\delta$  177.8, 177.1 (2C), 177.0, 176.8 (2C), 176.3, 176.2, 166.1, 165.8, 165.2, 165.1, 154.8, 153.1, 140.2, 136.6, 133.4, 133.2, 133.0 (2C), 129.8, 129.7, 129.7, 129.7, 129.6, 129.4, 128.9, 128.8, 128.4, 128.3, 128.2, 121.9, 111.4, 101.3, 99.3, 97.6, 97.1, 78.9, 76.1, 75.9, 75.0, 73.0, 72.1, 72.0, 71.9, 70.8, 70.4, 69.9, 69.8, 69.3, 69.1, 68.6, 68.1, 66.8, 63.3, 62.9, 60.5, 50.8, 49.4, 45.8, 41.0, 38.8, 38.8, 38.7, 38.6, 38.5, 37.1, 37.0, 35.4, 32.7, 32.3, 31.7, 30.6, 30.2, 29.8, 29.7, 29.5, 27.2, 27.1 (2C), 27.0 (3C), 26.6, 23.9, 20.4, 19.3, 18.0, 17.6, 17.2, 16.6, 8.7; MALDI-HRMS *m/z*: [M+Na]<sup>+</sup> calcd for C<sub>119</sub>H<sub>160</sub>O<sub>33</sub>Na, 2140.0734; found: 2140.0829. Compound **2b**: [ $\alpha$ ]<sub>D</sub><sup>25</sup> –16 (*c* 1.0, CHCl<sub>3</sub>); <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>):  $\delta$  7.98–7.73 (m, 8H), 7.50–7.16 (m, 12H), 5.83 (t, 1H, *J* = 9.0 Hz), 5.61 (t, 1H, *J* = 9.6 Hz), 5.47 (t, 1H, *J* = 9.3 Hz), 5.37–5.20 (m, 3H), 5.18–5.11 (m, 2H), 5.08–4.97 (m, 2H), 4.92 (s, 1H), 4.80 (s, 1H), 4.76 (d, 1H, *J* = 7.8 Hz), 4.70 (s, 1H), 4.61–4.50 (m, 2H), 4.48–4.30 (m, 3H), 4.23–4.14 (m, 1H), 4.12–4.04 (m, 1H), 3.92–3.80 (m, 1H), 3.76–3.62 (m, 3H), 3.62–3.46 (m, 2H), 3.38–3.28 (m, 1H), 2.62–1.94 (m, 9H), 1.90 (s, 3H), 0.96 (s, 3H), 0.84 (s, 3H), 0.75 (d, 3H, *J* = 6.6 Hz); <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>):  $\delta$  177.7, 177.1, 176.8, 176.2 (2C), 166.1, 165.8, 165.2, 165.0, 155.7, 140.2, 139.7, 135.3, 133.4, 133.1, 133.0, 129.8, 129.7, 129.4, 128.8, 128.3, 128.2, 126.8, 122.0, 101.3, 99.2, 97.6, 97.1, 78.9, 77.3, 76.1, 75.9, 74.9, 73.0, 72.1, 72.0, 71.9, 70.8, 70.4, 69.9, 69.8, 69.3, 69.1, 68.6, 68.1, 66.8, 63.2, 62.9, 61.5, 50.7, 44.1, 38.8, 38.8, 38.7, 38.5, 37.1, 36.9, 35.1, 32.8, 31.5, 30.5, 29.8, 29.6, 29.5, 27.1, 27.1, 27.0, 26.9, 25.7, 23.7, 20.6, 19.3, 17.2, 17.1, 16.6, 11.7; MALDI-HRMS *m/z*: [M+Na]<sup>+</sup> calcd for C<sub>119</sub>H<sub>160</sub>O<sub>32</sub>SNa, 2156.0506; found: 2156.0489. Compound **6**: [ $\alpha$ ]<sub>D</sub><sup>25</sup> –34 (*c* 0.8, CHCl<sub>3</sub>); <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>):  $\delta$  5.41–5.25 (m, 3H), 5.22–5.16 (m, 2H), 5.11–5.01 (m, 2H), 4.97 (s, 1H), 4.84 (s, 1H), 4.74 (s, 1H), 4.57 (d, 1H, *J* = 7.5 Hz), 4.50–4.34 (m, 2H), 4.23 (dd, 1H, *J* = 6.0, 12.0 Hz), 3.98–3.84 (m, 3H), 3.78–3.50 (m, 4H), 2.76–2.56 (m, 3H), 2.48–2.16 (m, 4H), 2.05 (s, 3H), 2.03 (s, 3H), 1.00 (s, 3H), 0.96 (d, 3H, *J* = 6.3 Hz), 0.92 (s, 3H); <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>):  $\delta$  177.7, 177.1, 177.0, 177.0, 176.8, 176.7, 176.2, 176.2, 171.1, 155.7, 140.1, 139.4, 135.6, 126.9, 121.9, 99.1, 97.6, 97.0, 78.8, 77.2, 76.0, 75.8, 71.9, 70.7, 70.3, 69.7, 69.2, 69.0, 69.0, 68.6, 68.0, 67.0, 63.1, 61.4, 50.6.

44.2, 38.8, 38.7, 38.6, 38.4, 37.1, 36.8, 35.2, 34.9, 32.1, 31.5, 30.4, 29.8, 29.5, 27.1, 27.0 (2C), 26.9, 25.7, 20.9, 20.5, 19.2, 17.2, 17.1, 16.7, 11.8; MALDI-HRMS  $m/z$ :  $[M+Na]^+$  calcd for  $C_{87}H_{136}O_{24}SNa$ , 1619.9035; found: 1619.9040. Compound **7**:  $[\alpha]_D^{25} -54$  ( $c$  0.8,  $CHCl_3$ );  $^1H$  NMR (300 MHz,  $CDCl_3$ ):  $\delta$  5.40 (d, 1H,  $J = 3.9$  Hz), 5.36–5.26 (m, 2H), 5.23–5.16 (m, 2H), 5.12–5.02 (m, 2H), 4.97 (s, 1H), 4.85 (s, 1H), 4.74 (s, 1H), 4.57 (d, 1H,  $J = 7.5$  Hz), 4.50–4.36 (m, 2H), 4.24 (dd, 1H,  $J = 5.4, 11.7$  Hz), 4.00–3.88 (m, 3H), 3.86 (s, 3H), 3.83 (s, 3H), 3.78–3.51 (m, 4H), 3.01 (dd, 1H,  $J = 6.1, 5.9$  Hz), 2.33 (s, 3H), 2.06 (s, 3H), 1.02 (s, 3H), 1.00 (s, 3H), 0.99 (d, 3H,  $J = 7.2$  Hz);  $^{13}C$  NMR (75 MHz,  $CDCl_3$ ):  $\delta$  177.8, 177.1, 177.1, 177.0, 176.8, 176.8, 176.3, 176.2, 171.2, 170.4, 167.6, 154.1, 142.4, 140.1, 137.1, 136.1, 132.4, 123.8, 122.0, 99.3, 97.6, 97.1, 79.0, 76.1, 75.9, 72.0, 70.8, 70.4, 69.8, 69.3, 69.1, 68.9, 68.7, 68.1, 66.8, 62.9, 56.5, 52.2, 52.0, 50.0, 47.2, 38.8, 38.8, 38.7, 38.5, 37.1, 36.7, 36.5, 34.1, 33.1, 32.7, 31.5, 30.7, 29.9, 29.7, 28.2, 27.2, 27.1, 27.1, 27.1, 27.0, 21.1, 20.9, 19.3, 17.3, 16.7, 16.2, 14.9; MALDI-HRMS  $m/z$ : calcd for  $[M+Na]^+$   $C_{93}H_{142}O_{28}Na$ , 1729.9580; found: 1729.9602. Compound **12**:  $[\alpha]_D^{25} -33$  ( $c$  0.3,  $CHCl_3$ );  $^1H$  NMR (300 MHz,  $CDCl_3$ ):  $\delta$  8.05–7.80 (m, 8H), 7.58–7.24 (m, 12H), 5.90 (t, 1H,  $J = 9.6$  Hz), 5.69 (t, 1H,  $J = 9.6$  Hz), 5.53 (t, 1H,  $J = 9.0$  Hz), 5.42 (d, 1H,  $J = 3.6$  Hz), 5.39–5.28 (m, 2H), 5.25–5.19 (m, 2H), 5.15–5.05 (m, 2H), 5.00 (s, 1H), 4.88 (s, 1H), 4.84 (d, 1H,  $J = 7.8$  Hz), 4.77 (s, 1H), 4.65 (dd, 1H,  $J = 3.0, 12.3$  Hz), 4.60 (d, 1H,  $J = 7.2$  Hz), 4.56–4.38 (m, 3H), 4.26 (dd, 1H,  $J = 5.4, 12.0$  Hz), 4.21–4.12 (m, 1H), 3.99–3.90 (m, 1H), 3.84 (s, 3H), 3.82 (s, 3H), 3.79–3.54 (m, 4H), 3.42–3.34 (m, 1H), 3.00 (dd, 1H,  $J = 6.6, 16.2$  Hz), 2.21 (s, 3H), 1.04 (s, 3H), 0.96 (s, 3H), 0.84 (d, 3H,

$J = 6.6$  Hz);  $^{13}C$  NMR (75 MHz,  $CDCl_3$ ):  $\delta$  177.7, 177.1, 177.0, 176.8 (2C), 176.3, 176.2, 170.4, 167.7, 166.1, 165.8, 165.2, 165.1, 153.8, 142.0, 140.1, 137.4, 136.4, 133.4, 133.2, 133.0, 133.0, 132.2, 129.8, 129.7, 129.6, 129.4, 128.9, 128.9, 128.4, 128.3, 128.3, 128.2, 123.6, 122.0, 101.5, 99.4, 97.4, 97.1, 79.0, 76.1, 75.9, 75.0, 73.0, 72.2, 72.1, 72.0, 70.9, 70.4, 69.9, 69.8, 69.4, 69.1, 68.7, 68.1, 66.8, 63.3, 63.0, 56.5, 52.1, 51.9, 50.1, 47.1, 38.8, 38.8, 38.7, 38.5, 37.1, 36.7, 36.4, 34.0, 33.8, 32.7, 31.5, 30.7, 29.9, 29.7, 28.4, 27.6, 27.2, 27.1 (3C), 27.0, 21.0, 19.3, 17.3, 16.6, 16.1, 14.8; MALDI-HRMS  $m/z$ :  $[M+Na]^+$  calcd for  $C_{125}H_{166}O_{36}Na$ , 2266.1051; found: 2266.1071. Compound **8a/b**:  $^1H$  NMR (300 MHz,  $CDCl_3$ ):  $\delta$  7.57 (s, 0.3H), 7.44 (s, 0.7H), 5.45–5.26 (m, 3H), 5.24–5.16 (m, 2H), 5.13–5.03 (m, 2H), 4.98 (s, 1H), 4.86 (s, 1H), 4.75 (s, 1H), 4.58 (d, 1H,  $J = 7.8$  Hz), 4.52–4.36 (m, 2H), 4.24 (dd, 1H,  $J = 5.7, 12.0$  Hz), 4.05–3.88 (m, 3H), 3.86 (s, 1H), 3.84 (s, 2H), 3.80–3.50 (m, 4H), 3.26 (dd, 0.3H,  $J = 6.0, 16.8$  Hz), 2.31 (s, 3H), 2.05 (s, 3H), 1.05–0.99 (m, 9H); MALDI-HRMS  $m/z$ :  $[M+Na]^+$  calcd for  $C_{91}H_{140}O_{26}Na$ , 1671.9525; found: 1671.9501. Compound **13a/b**:  $^1H$  NMR (300 MHz,  $CDCl_3$ ):  $\delta$  8.05–7.80 (m, 8H), 7.56–7.23 (m, 13H), 5.90 (t, 1H,  $J = 9.3$  Hz), 5.69 (t, 1H,  $J = 9.9$  Hz), 5.54 (t, 1H,  $J = 7.8$  Hz), 5.42 (br s, 1H), 5.38–5.27 (m, 2H), 5.25–5.18 (m, 2H), 5.14–5.04 (m, 2H), 4.99 (s, 1H), 4.87 (s, 1H), 4.83 (d, 1H,  $J = 7.8$  Hz), 4.77 (s, 1H), 4.69–4.56 (m, 2H), 4.55–4.38 (m, 3H), 4.25 (dd, 1H,  $J = 5.1, 12.3$  Hz), 4.21–4.12 (m, 1H), 3.99–3.89 (m, 1H), 3.86 (s, 1.3H), 3.81 (s, 1.7H), 3.79–3.53 (m, 4H), 3.49–3.36 (m, 1H), 3.27 (dd, 0.3H,  $J = 6.9, 16.8$  Hz), 2.22 (s, 1.3H), 2.21 (s, 1.7H), 1.03 (s, 3H), 0.97 (s, 3H), 0.86 (m, 3H); MALDI-HRMS  $m/z$ :  $[M+Na]^+$  calcd for  $C_{123}H_{164}O_{34}Na$ , 2208.0996; found: 2208.0993.